OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Susan Haigney is managing editor of BioPharm International, firstname.lastname@example.org.
CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.
The COVID-19 pandemic has triggered additional considerations to supplier oversight of contract manufacturing facilities.
The agency’s focus appears to be on generic drugs for the upcoming year.
Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.